Brief Article
Copyright ©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 7, 2011; 17(45): 5007-5013
Published online Dec 7, 2011. doi: 10.3748/wjg.v17.i45.5007
Table 1 Patient characteristics by fibrosis rates (by Poynard)
Slow fibrosersFast fibrosersP value
(n = 116)(n = 52)
Female (%)37%31%0.43
Age (yr)49.8 ± 10.543.9 ± 7.1 < 0.001
Age at infection (yr)25.1 ± 10.825.2 ± 7.70.97
Infection duration (yr)24.7 ± 818.7 ± 8.1 < 0.001
Alcohol intake ≥ 50 g/d7.1%10.4%0.53
BMI (kg/m2)23.8 ± 2.923.4 ± 3.10.5
Genotype (%)0.49
174.3%62.8%
22.8%2.3%
316.5%23.3%
46.4%11.6%
Inflammatory score, grade (units)1.3 ± 0.681.81 ± 0.69 < 0.001
Fibrosis stage (%) < 0.001
014.7%0%
145.7%9.6%
229.3%5.8%
38.6%48.1%
41.7%36.5%
Table 2 Frequency of hypercoagulation mutations (%)
Mutation typeWild typeHeterozygoteHomozygote
Factor V Leiden (n = 159)96.23.80
Prothrombin 20210 (n = 156)92.37.10.6
MTHFR (n = 163)35.650.913.5
Table 3 Percentage of hypercoagulation gene mutation carriage by rate of fibrosis (by Poynard)
GeneMutation carriagePercent of slow fibrosersPercent of fast fibrosersP value
PT20210Wild type94.586.90.181
Heterozygote5.510.9
Homozygote02.2
Factor V LeidenWild type95.5980.67
Heterozygote4.52
Homozygote00
MTHFRWild type35.6360.80
Heterozygote5248
Homozygote12.416
Table 4 Prothrombin 20210 mutation rates in various “fibrosis rate” models
Rate of fibrosisPT20210 mutation in slow fibrosers (%)PT20210 mutation in fast fibrosers (%)P value3
Rate of fibrosis by Poynard5.50130.18
0.13 units/yr15.1015.800.07
0.133 units/yr2516.700.03
Table 5 Linear regression analysis of rate of fibrosis
Predictive variableR2P value
PT20210 status0.0930.002
Age0.0220.033
Gender0.0160.042
Age of infection0.167< 0.001
BMINot contributing
Alcohol consumptionNot contributing
Inflammation grade0.121< 0.001
Table 6 Multivariate analysis of the association between rate of liver fibrosis (slow fibrosers vs fast fibrosers) predicted by prothrombin 20210 mutation and various known parameters
ParameterOR (95% CI)P-wald1
Age0.91 (0.86-0.96)< 0.001
PT202104.76 (1.13-19.99) 0.033
Inflammation grade27.42 (3.07-17.95)< 0.001